当前位置: 首页> 动保> 正文
重磅!拜耳动保业务或将与礼蓝动保合并
发布时间:2019-09-23 08:57来源:农财宝典

8月8日,据国外知名网站“Fierce Pharma”报道,拜耳和礼蓝(Elanco)的动保业务将在下周合并。

8月8日,据国外知名网站“Fierce Pharma”报道,拜耳和礼蓝(Elanco)的动保业务将在下周合并。

一年前拜耳可能计划剥离动保业务的传言刚出现的时候,从礼来(Eli Lilly)独立而出的礼蓝(Elanco)并不是市场观察者的买家列表中可能性最高一家,尤其是在几家私募投资公司对其表示明显兴趣之后。

据路透社援引某业内人士的消息称,两家公司可能最快会在下周宣布达成合并协议。该知情人士称,交易的一部分礼蓝将使用股票支付,具体可能会在下周的季度报告中宣布。

对于FiercePharma网站的评论,礼蓝的一位发言人拒绝回应。而拜耳的一位发言人在电子邮件中表示,该公司正在退出动保业务的“路上”。“在对退出动保业务的方案进行战略评估后,主要关注点是出售,然而拜耳也继续考虑所有价值最大化的选项。”他说。

以下为Fierce Pharma网站原文:

Bayer, Elanco could lock up animal health merger next week: report

When rumors emerged nearly a year ago that Bayer might be planning to exit the animal-health business, Eli Lilly spinoff Elanco was not at the top of any market-watcher’s list of potential buyers—especially not after it became clear that several private equity players were interested in the asset.

Turns out Elanco was interested, and the two companies could announce an agreement to merge as soon as next week, Reuters reports, citing unnamed sources. Elanco would pay for the deal partly in stock, and it could be aiming to time the announcement with its quarterly report next week, the sources said.

A spokesperson for Elanco declined to comment to FiercePharma. A spokesperson for Bayer said in an email that the company is “on track” to exit animal health. “Following a strategic review of exit options, the primary focus is on a sale. However, Bayer also continues to consider all value-maximizing options,” he said.

来源:Fierce Pharma

翻译:农财宝典记者王之娴


0
广告
广告
广告
广告
本文所载文章、数据仅供参考,使用前请核实,风险自负
Copyright © 2011 www.boyar.cn 博亚和讯
京ICP备13008321号-1
公安部备案 11010802029875